Investor Presentation Full Year 2021
8
Investor presentation Full year 2021
Biopharm sales grew by 4% driven by both North America
Operations and International Operations
DKK
billion
25
20
20
Reported Biopharm sales
Growth at CER
4%
9%
25%
25%
4%
-2%
•
•
Biopharm sales driven by global commercial execution
Biopharm sales growth driven by:
6% growth in North America Operations
3% sales growth in International Operations
Rare blood disorders sales increased by 9%, driven by:
Uptake of launch products Esperoct® and Refixia®
15
Rare blood disorders
10
5
•
Novo Eight® and NovoSevenⓇ
Rare endocrine disorders sales decreased by 2% driven by:
•
North America Operations sales declined by 12% partly offset by
sales growth in International Operations of 5%
•
Novo Nordisk is the leading company in the global human
growth disorder market with a value market share of ~36.3%
0
Total1
Rare
blood
Haem.
A
Haem.
B
Novo- !
SevenⓇ
disorders²
Rare
endocrine
disorders³
1 Total includes "Other Biopharm", which consists of primarily Vagifem® and Activelle®: 2 Comprises Novo Seven®, Novo Eight®, Esperoct®, RefixiaⓇ and NovoThirteenⓇ; 3 Primarily NorditropinⓇ.
Note: NovoThirteenⓇ is not shown for Rare blood disorders.
Haem. A: Haemophilia A; Haem. B: Haemophilia B; Unless otherwise specified, sales growth is at constant exchange rates
Novo NordiskⓇView entire presentation